Pharmacy Daily | RB responds on Nurofen ads

RECKITT Benckiser says it’s preparing a response to the TGA Complaints Resolution Panel (CRP) ruling against its Nurofen TV ads (PD Wed), saying it does not agree with “a number of the sanctions requested,” which include withdrawing the commercials. In a statement issued following reportage of the CRP judgement, the company insisted that consumers will “continue to see the familiar branding of the Nurofen target and messages of Nurofen working at the site of pain”. That’s despite the CRP ruling that claims made in the ads that Nurofen provides “targeted relief from pain” and goes “straight to the source of pain” were misleading for consumers. The company pointed out that the TGA holds no question in relation to the product’s safety and efficacy information in any of its advertising and packaging. “Nurofen continually strives to provide advertising and packaging that is simple to understand while giving the consumer relevant information relating to the use of its products,” RB said.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 09 Sep 11
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Sep 11